Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure

Journal of Cardiac Failure

Volumn 17, Issue 12, 2011, Pages 982-989

  Goldsmith, Steven R ^a   Gilbertson, David T ^b   MacKedanz, Shari A ^a   Swan, Suzanne K ^c  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c DAVITA CLINICAL RESEARCH   (United States)

Author keywords

diuretics; Heart failure; neurohormones; vasopressin antagonists

Indexed keywords

ARGIPRESSIN; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CONIVAPTAN; FUROSEMIDE; IOTALAMIC ACID; NEUROHORMONE; RENIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; URINARY EXCRETION; URINE VOLUME;

BENZAZEPINES; BLOOD PRESSURE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; RECEPTORS, VASOPRESSIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84855972579     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2011.08.012     Document Type: Article

References (17)

1. G.M. Felker, C.M. O'Connor, and E. Braunwald Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2 2009 56 62
2. G.S. Francis, R.M. Siegel, S.R. Goldsmith, M.T. Olivari, T.B. Levine, and J.N. Cohn Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis Ann Intern Med 103 1985 1 6 (Pubitemid 15068490)
3. S.S. Gottlieb, S.L. Skettino, A. Wolff, E. Beckman, M.L. Fisher, and R. Freudenberger Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure J Am Coll Cardiol 35 2000 56 59 (Pubitemid 30061259)
4. V. Hasselblad, S.W. Gattis, M.R. Shah, Y. Lokhnygina, C.M. O'Connor, and R.M. Califf Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial Eur J Heart Fail 9 2007 1064 1069 (Pubitemid 47451811)
5. G.M. Felker, K.L. Lee, D.A. Bull, M.M. Redfield, L.W. Stevenson, and S.R. Goldsmith Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797 805
6. M.R. Costanzo, M.E. Guglin, M.T. Saltzberg, M.L. Jessup, B.A. Bart, and J.R. Teerlink Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 2007 675 683 (Pubitemid 46205043)
7. J.G. Verbalis Vasopressin V2 receptor antagonists J Mol Endocrinol 29 2002 1 9
8. S.R. Goldsmith, U. Elkayam, W.H. Haught, A. Barve, and W. He Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study J Card Fail 14 2008 641 647
9. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1331 (Pubitemid 46513233)
10. L.C. Costello-Boerrigter, W.B. Smith, G. Boerrigter, J. Ouyang, C.A. Zimmer, and C. Orlandi Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Renal Physiol 290 2006 F273 F278
11. N. Lawendy, S. Krishnaswami, R. Wang, D. Gruben, C. Cannon, and S. Swan Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers J Clin Pharmacol 49 2009 423 429
12. J.E. Udelson, C. Orlandi, T. O'Brien, R. Sequeira, J. Ouyang, and M.A. Konstam Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, ramdomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract] J Am Col Cardiol 39 Suppl 2002 156A
13. S.R. Goldsmith, G. Francis, and J.N. Cohn Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure Am J Cardiol 64 1989 1382 1385 (Pubitemid 20000096)
14. J. Perucca, D.G. Bichet, P. Bardoux, N. Bouby, and L. Bankir Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists J Am Soc Nephrol 19 2008 1721 1731
15. J.E. Udelson, W.B. Smith, G.H. Hendrix, C.A. Painchaud, M. Ghazzi, and I. Thomas Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2001 2417 2423 (Pubitemid 33108374)
16. J.E. Udelson, C. Orlandi, J. Ouyang, H. Krasa, C.A. Zimmer, and G. Frivold Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol 52 2008 1540 1545
17. S.R. Goldsmith, F. Brandimarte, and M. Gheorghiade Congestion as a therapeutic target in acute heart failure syndromes Prog Cardiovasc Dis 52 2010 383 392